In patients with liver disease, PCC therapy was effective in improving coagulation test results without an excess of thrombotic events.

20 мар. 2023 г. · The impact of PCC in in-vitro spiking experiments of cirrhotic plasma is promising, but also warrants cautious use in light of thromboembolic ...

Therefore, we aimed to assess the association of PCC substi- tution with the risk of thromboembolic events in patients with decompensated liver cirrhosis. To ...

Mortality was higher in the PCC group. PCC group patients had more severe cirrhosis and higher INR. Results could have been impacted by a treatment bias in ...

Abstract. A 4-factor prothrombin complex concentrate (4F-PCC, Kcentra®) was recently approved in the United States for the reversal of.

In this review, we will discuss the use of 4F-PCC in four critical bleeding settings: cardiac surgery, major trauma, end-stage liver disease, and oral anti-Xa ...

29 мая 2023 г. · The primary aim of this review was to assess the clinical effectiveness of PCCs in reducing transfusion requirements in patients undergoing liver ...

15 нояб. 2013 г. · PCC is less effective in patients with Child-Pugh C cirrhosis and acute liver failure. This might be due to deficit in coagulation factors such ...

11 сент. 2019 г. · Prothrombin complex concentrate (PCC) is FDA approved for warfarin reversal but is often used for coagulopathy and hemorrhage in patients with liver disease.

8 сент. 2020 г. · PCC appears to be an effective treatment for acquired coagulopathy in patients with ESLD undergoing LT who have received pharmacologic ...